Universal Ibogaine Announces Board Changes

(TheNewswire)

Calgary, AB – September 23, 2025 – TheNewswire - Universal Ibogaine Inc.(TSXV: IBO) OTC: IBOGF (the “Company”),

The Universal Ibogaine Board of directors bringstogether expertise in healthcare , clinical trials,  financial, andlegal patient safety ensuring a strong foundation to guide the companythrough its next phase with confidence.

As part of the transition, Peter Vlahos, ConstantineBuzunis, Ken Cranwill, and Peter Ginakes will no longer be part of theBoard of Directors and have resigned.

Universal Ibogaine confirms its Board member list ofEric Hrimech, Nia Killebrew, Tony Wagner, James Duncan, Nick Karos asthe organization advances toward submitting its clinical trialapplication to Health Canada by the end of November 2025.

About Universal IbogaineInc.

UI is a life sciences company with a mission totransform addiction treatment using medicalized ibogaine through aplanned Canadian clinical trial focused on opioid use disorder, andultimately to utilize that treatment protocol globally through plannedfuture licensing agreements.  UI is concurrently developing a stateof the art holistic addiction treatment protocol at its KelburnRecovery Centre (located near Winnipeg, Manitoba) that, which whenpaired with the planned ibogaine detox protocol, is intended torevolutionize the way we treat addiction and drastically improve thelives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NORITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THEPOLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THEADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDINGFORWARD-LOOKING STATEMENTS

This news release may contain forward-lookingstatements and information. Forward-looking information is frequentlycharacterized by words such as "plans", “planned”,"expect", "project", "intends",“intended”, "will", "believe","anticipate", "estimate", "scheduled","potential", or other similar words, or statements thatcertain events or conditions "may", "should" or"could" occur.  The forward-looking statements andinformation are based on certain key expectations and assumptions madeby UI at the date the statements are made.  Although UI believes thatthe expectations and assumptions on which the forward-lookingstatements are based are reasonable, undue reliance should not beplaced on the forward-looking statements because UI can give noassurance that they will prove to be correct.

Since forward-looking statements address future eventsand conditions, by their very nature they involve inherent risks anduncertainties. Actual results could differ materially from thosecurrently anticipated due to a number of factors and risks, whichinclude, but are not limited to, risks that required regulatoryapprovals are not obtained. The reader is cautioned that assumptionsused in the preparation of such information, although consideredreasonable by UI at the time of preparation, may prove to be incorrectand readers are cautioned not to place undue reliance onforward-looking information, which speaks only to conditions as of thedate hereof. UI does not undertake any obligation to release publiclyany revisions to forward-looking information contained herein toreflect events or circumstances that occur after the date hereof or toreflect the occurrence of unanticipated events, except as may berequired under applicable securities laws.

Additional information identifying risks anduncertainties that could affect financial results and the Company iscontained in the Company’s filings with Canadian securitiesregulators, which are available at www.sedar.com

For further information :

Nick Karos, CEO

Universal Ibogaine Inc.

612-567-0770

Nick.Karos@universalibogaine.com

RelatedLinks : https://universalibogaine.com

Copyright (c) 2025 TheNewswire - All rights reserved.